Literature DB >> 16625114

Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia.

Anita W Rijneveld1, Sebastiaan Weijer, Paul Bresser, Sandrine Florquin, George P Vlasuk, William E Rote, C Arnold Spek, Pieter H Reitsma, Jaring S van der Zee, Marcel Levi, Tom van der Poll.   

Abstract

OBJECTIVE: The tissue factor (TF)-factor VIIa (FVIIa) complex not only is essential for activation of blood coagulation but also affect the inflammatory response during sepsis. The objective of this study was to determine the role of TF-FVIIa in pneumonia caused by Streptococcus pneumoniae, the most important causative organism in community-acquired pneumonia and a major cause of sepsis.
DESIGN: A controlled, in vivo laboratory study.
SETTING: Research laboratory of a health sciences university. PATIENTS AND
SUBJECTS: Patients with unilateral community-acquired pneumonia and female BALB/c mice.
INTERVENTIONS: Bilateral bronchoalveolar lavage was performed in patients with community-acquired pneumonia. In mice, pneumonia was induced by intranasal inoculation with S. pneumoniae with or without concurrent inhibition of TF-FVIIa by subcutaneous injections of recombinant nematode anticoagulant protein (rNAPc2).
MEASUREMENTS AND MAIN RESULTS: Patients with unilateral community-acquired pneumonia demonstrated elevated concentrations of FVIIa, soluble TF, and thrombin-antithrombin complexes in bronchoalveolar lavage fluid obtained from the infected site compared with the uninfected site. Mice with S. pneumoniae pneumonia displayed increased TF expression and fibrin deposits in lungs together with elevated thrombin-antithrombin complex levels in bronchoalveolar lavage fluid; inhibition of TF-FVIIa by rNAPc2 attenuated the procoagulant response in the lung but did not affect host defense, as reflected by an unaltered outgrowth of pneumococci and an unchanged survival.
CONCLUSIONS: These data suggest that TF-FVIIa activity contributes to activation of coagulation in the lung during pneumococcal pneumonia but does not play an important role in the antibacterial host defense in this murine model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16625114     DOI: 10.1097/01.CCM.0000218807.20570.C2

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  27 in total

1.  Endogenous tissue factor pathway inhibitor has a limited effect on host defence in murine pneumococcal pneumonia.

Authors:  Florry E van den Boogaard; Cornelis van 't Veer; Joris J T H Roelofs; Joost C M Meijers; Marcus J Schultz; George J Broze; Tom van der Poll
Journal:  Thromb Haemost       Date:  2015-04-02       Impact factor: 5.249

2.  Tissue factor expression by myeloid cells contributes to protective immune response against Mycobacterium tuberculosis infection.

Authors:  Sambasivan Venkatasubramanian; Deepak Tripathi; Torry Tucker; Padmaja Paidipally; Satyanarayana Cheekatla; Elwyn Welch; Anjana Raghunath; Ann Jeffers; Amy R Tvinnereim; Melissa E Schechter; Bruno B Andrade; Nizel Mackman; Steven Idell; Ramakrishna Vankayalapati
Journal:  Eur J Immunol       Date:  2015-11-10       Impact factor: 5.532

3.  Abstracts of the 16th European Congress of Clinical Microbiology and Infectious Diseases. Nice, France. April 1-4, 2006.

Authors: 
Journal:  Clin Microbiol Infect       Date:  2006-04       Impact factor: 8.067

4.  EPCR-dependent PAR2 activation by the blood coagulation initiation complex regulates LPS-triggered interferon responses in mice.

Authors:  Hai Po H Liang; Edward J Kerschen; Irene Hernandez; Sreemanti Basu; Mark Zogg; Fady Botros; Shuang Jia; Martin J Hessner; John H Griffin; Wolfram Ruf; Hartmut Weiler
Journal:  Blood       Date:  2015-03-02       Impact factor: 22.113

5.  Association between urokinase haplotypes and outcome from infection-associated acute lung injury.

Authors:  John Arcaroli; Jeff Sankoff; Nianjun Liu; David B Allison; James Maloney; Edward Abraham
Journal:  Intensive Care Med       Date:  2007-11-10       Impact factor: 17.440

6.  Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study.

Authors:  Marcel Schouten; Koenraad F van der Sluijs; Bruce Gerlitz; Brian W Grinnell; Joris J T H Roelofs; Marcel M Levi; Cornelis van 't Veer; Tom van der Poll
Journal:  Crit Care       Date:  2010-04-14       Impact factor: 9.097

7.  Impact of the factor V Leiden mutation on the outcome of pneumococcal pneumonia: a controlled laboratory study.

Authors:  Marcel Schouten; Cornelis van't Veer; Joris J T H Roelofs; Marcel Levi; Tom van der Poll
Journal:  Crit Care       Date:  2010-08-03       Impact factor: 9.097

8.  Prevalence and significance of coagulation abnormalities in community-acquired pneumonia.

Authors:  Eric B Milbrandt; Michael C Reade; MinJae Lee; Stephanie L Shook; Derek C Angus; Lan Kong; Melinda Carter; Donald M Yealy; John A Kellum
Journal:  Mol Med       Date:  2009-09-08       Impact factor: 6.354

9.  Organ failure in sepsis.

Authors:  Herwig Gerlach; Susanne Toussaint
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

10.  Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats.

Authors:  Jorrit J Hofstra; Alexander D Cornet; Bart F de Rooy; Alexander P Vlaar; Tom van der Poll; Marcel Levi; Sebastian Aj Zaat; Marcus J Schultz
Journal:  Crit Care       Date:  2009-09-09       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.